From the Research
The AVISE CTD test for collagenosis has a sensitivity of approximately 83% and a specificity of about 86%, as reported in the most recent and highest quality study 1. This blood test helps diagnose lupus and other connective tissue diseases by measuring multiple biomarkers, including cell-bound complement activation products (CB-CAPs), autoantibodies, and other immunological markers. The test is particularly useful in cases where traditional diagnostic methods yield unclear results, as it provides a more comprehensive assessment of immune system activity. Some key points to consider when interpreting the results of the AVISE CTD test include:
- The higher specificity means fewer false positives compared to traditional testing methods, while the improved sensitivity helps identify patients who might be missed by standard tests.
- Physicians typically use AVISE testing as part of a comprehensive diagnostic approach that includes clinical evaluation, medical history, and other laboratory tests, rather than as a standalone diagnostic tool.
- The test has been validated in clinical studies, with one study finding that 87% of cases with a positive test result were diagnosed with SLE, compared to 17% of controls 1.
- Other studies have reported associations between collagenosis and various conditions, including diabetes, scleredema, and Gardner's syndrome 2, 3, 4, but these findings are not directly relevant to the sensitivity and specificity of the AVISE CTD test.
- A recent study found that venous collagenosis may play a role in the pathogenesis of white matter hyperintensity, highlighting the importance of considering vascular risk factors in the diagnosis and management of collagenosis 5.